[Kim Saemi, Edaily Reporter] Samsung Bioepis announced on July 2 that it has signed a domestic partnership agreement with Boryung for the sales of ‘Exbrick,’ a biosimilar referencing Xgeva, a treatment for bone disorders.

CI of Samsung Bioepis and Boryung (Source: Both Companies)

Under the agreement, Samsung Bioepis, as the developer, will be responsible for manufacturing and supplying Exbrick, while Boryung will take charge of exclusive domestic sales and marketing.

Xgeva, developed by Amgen, is indicated for the prevention of skeletal-related events (SREs) in patients with bone metastases and for the treatment of giant cell tumor of bone. As of 2024, its global sales reach approximately 3.3 trillion KRW.

Through this agreement, Samsung Bioepis and Boryung are expanding their domestic biosimilar partnership portfolio to include Exbrick, following their collaboration on the oncology biosimilars Onbevzi (Avastin biosimilar) and Samfenet (Herceptin biosimilar), thereby strengthening their strategic alliance.

The partnership products have shown strong growth momentum. For instance, Onbevzi recorded sales of 45.2 billion KRW last year.

Boryung, which holds the top domestic market share among Korean pharmaceutical companies in oncology, operates the country’s largest specialized sales force and offers a wide range of therapeutic options, from supportive oncology medications to biosimilars.

Samsung Bioepis obtained domestic marketing approval for Exbrick in May and had previously secured approval in the U.S. and Europe this February.

Kyung-Ah Kim, CEO of Samsung Bioepis, stated, “We will work closely with Boryung to expand treatment access through biologics for more patients in Korea, leveraging our product capabilities and Boryung’s commercial strength.”

Jung-Kyun Kim, CEO of Boryung, added, “We are pleased to add another high-quality biosimilar developed by Samsung Bioepis to our portfolio. Based on the proven synergy from our existing partnerships, we will do our utmost to ensure Exbrick gains early traction in the market.”